Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Identifying cards that offer both cash back and travel points can enhance your rewards experience. Explore your options for better benefits.
28,655 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Researchers unveil an autonomous AI-driven worm that can learn and spread across networks without human input, signal...
PIMCO dismisses Trump’s NATO exit threats as noise, calling them a paper tiger. The note arrives as investors weigh t...
A niche AI hardware stock is drawing investors as hyperscale data centers surge. Analysts say this stock could easies...
Markets react as reports surface that the u.s.-iran deal nears, paired with warnings from a Trump ally about Tehran’s...
LBank will stage a VIP Matchday around the Argentina vs Austria World Cup 2026 clash at AT&T Stadium in Dallas, spotl...
A high-profile insider sale at PTC Therapeutics coincides with a milestone for product revenue. This article breaks d...
As defense budgets stabilize and technology explodes, investors are re-pricing defense names. This piece examines why...
A Boston judge voided the $100,000 H-1B visa fee, creating a split with a ruling that upheld it. The dispute now head...
Regulators warn of a loophole that allows new chemicals to enter foods and supplements without premarket approval. Th...
Minneapolis Fed President Neel Kashkari now says one more rate hike may be on the table this year, reversing an earli...
A new mega-listing grabbed headlines by raising $26.5 billion, ranking just below SpaceX in U.S. market history. Read...